“…Treatment, toxicities, side effects, complications and information on second-and third-line treatments after recurrent disease were variously reported as having been discussed with patients before making decisions, sometimes by using written materials or by providing access to psychologists or social workers [18,20,23,38,42,52,53,56,58,59,61,64]. A number of papers identified the need to take into account patients' physical and psychological comorbidities when making clinical decisions; furthermore, they noted that special attention should be paid to provide the same clinical message and bridging gaps between teams and patients, as well as clearly setting out how to deal with the complexities of the health care system [43,44,53,54,56,60,63]. Other studies addressed issues such as the patient-doctor relationship within a multidisciplinary setting, the impact of pre-existing knowledge of the patient in MDT discussions, patient attendance at and involvement in MDT meetings, and the way in which the patients are approached to participate in clinical trials [46,48,56,64].…”